CD82 encodes a transmembrane glycoprotein of tetraspanins family, and functions as a tumor metastasis suppressor. We performed a systematic meta and bioinformatics analysis through multiple online databases up to March 14, 2017. We¬ found down-regulated CD82 expression in gastric cancer, compared with normal mucosa (p < 0.05). CD82 expression was negatively with depth of invasion, lymph node and distant metastasis, TNM staging and dedifferentiation of gastric cancer (p < 0.05). A positive association between CD82 expression and favorable overall survival was found in patients with gastric cancer (p < 0.005). According to bioinformatics analysis, CD82 mRNA expression was higher in gastric cancer than normal tissues (p < 0.05). According to Kaplan-Meier plotter and TCGA database, we found that a higher CD82 expression was positively correlated with overall or progression-free survival rates of all cancer patients, even stratified by aggressive parameters or as an independent factor (p < 0.05). These findings indicated that CD82 expression might be employed as a potential marker to indicate gastric carcinogenesis and subsequent progression, even favorable prognosis.